@article{article, title = {{Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation}}, url = {{http://eprints.whiterose.ac.uk/99486/ }}, year = {{2016}}, month = {{4}}, author = {{Stevenson M and Archer R and Tosh J and Simpson E and Everson-Hock E and Stevens J and Hernandez-Alava M and Paisley S and Dickinson K and Scott D and Young A et al}}, doi = {{10.3310/hta20350}}, volume = {{20}}, journal = {{Health Technology Assessment}}, issue = {{35}}, pages = {{1-610}}, note = {{Accessed on 2025/04/11}}}